A 6-month trial assessing the safety and efficacy of cyclosporine treatment in patients with active rheumatoid arthritis

Journal Title: Reumatologia - Year 2005, Vol 43, Issue 5

Abstract

Objective: The objective of this study was to determine efficacy and safety of the new generic cyclosporin formulation, Equoral capsules administered in monoterapia or in combination with other disease-modifying anti-rheumatic drugs in patients with active rheumatoid arthritis (RA). Methods: Thirty patients receiving CsA for RA were prospectively studied over a mean treatment period of 6 months. Initially CsA was given orally 2.5 mg/kg/day. In the course of the observation the dose ranged between 2.5 and 4 mg/kg/day. Clinical evaluation for RA disease activity tender and swollen joint, VASP, patient’s and physician’s global assessments, morning stiffness duration, HAQ, ESR, CRP and treatment side effects was performed prior and to each visit. We studied also the pharmacokinetics of Equoral The occurence of adverse reactions was noted. Results: 18 patients (60%) completed 6 months study. Treatment terminations were due to adverse events in 6 cases, inefficacy in 4 patients, poor compliance in 2 patients. In 18 patients who completed 6 months of therapy, a significant improvement was noted compared to baseline in 6 out of 9 clinical disease variables and acute phase reactants. In terms of efficacy at 6 months of follow-up 12 of patients had a ACR 20%, 7 a 50% ACR, 3 a 70% ACR response. The DAS28 index dropped significantly from 4.8±0.9 at baseline visit to 3.3±1.5 (p

Authors and Affiliations

Jerzy Świerkot, Katarzyna Gruszecka-Marczyńska, Jacek Szechiński

Keywords

Related Articles

Standaryzacja metod oznaczania autoprzeciwciał markerowych w ramach ECFS – cele a realne efekty

Autoimmunizacja to stan permanentnej obecności w surowicach pacjentów autoprzeciwciał i autoreaktywnych limfocytów T, które występują i są zaangażowane w patomechanizmy występujące także w chorobach tkanki łącznej. Poza...

Evaluation of 12-lead resting ECG with QTc analysis in children with systemic and localized scleroderma

Scleroderma is chronic inflammatory disease of connective tissue of unknown etiology. Classification into two forms: systemic and localized scleroderma depends on type of skin symptoms, kind of immunological disturbances...

The comparison of efficacy and assessment of influence on intensity of inflammatory process in recurrent knee joint effusions treated by the use of chemical and radiosynoviorthesis

The therapy of recurrent knee joint effusions of patients with rheumatoid arthritis (RA) and spondyloarthropaties (Spa) is still the challenge for rheumatologists. Chemical synoviorthesis and radiosynoviorthesis belong t...

Samoistna mieszana krioglobulinemia typu II – dobry wynik leczenia

Krioglobulinemia jest układowym schorzeniem o charakterze zapalenia naczyń, charakteryzującym się obecnością krążących we krwi kompleksów immunologicznych, wykazujących właściwości precypitacji w niskich temperaturach....

In-patients as a source of medical information for patients admitted to the rheumatological ward

One hundred patients admitted to the rheumatological ward were questioned concerning the will to discuss their medical problems with other in-patients and the impact of such obtained data on their attitude to medical pro...

Download PDF file
  • EP ID EP83604
  • DOI -
  • Views 94
  • Downloads 0

How To Cite

Jerzy Świerkot, Katarzyna Gruszecka-Marczyńska, Jacek Szechiński (2005). A 6-month trial assessing the safety and efficacy of cyclosporine treatment in patients with active rheumatoid arthritis. Reumatologia, 43(5), 257-264. https://www.europub.co.uk/articles/-A-83604